Prescription medicine

Meropenem and vaborbactam Brand names: Vabomere

Meropenem and vaborbactam (Vabomere) is a prescription medicine with an FDA approval on record since 2017. No generic is listed in FDA's NDC Directory.

No generic listed

Check it at the source: the meropenem and vaborbactam FDA label on DailyMed (effective February 27, 2026, Melinta Therapeutics, LLC); the NDA 209776 record on Drugs@FDA; every meropenem and vaborbactam label on DailyMed.

Highlights of the record

FDA label of February 27, 2026; NDC Directory, Drugs@FDA and Orange Book, October 8, 2026

Used for

From the label: indications and usage
VABOMERE (meropenem and vaborbactam) is a combination of meropenem, a penem antibacterial, and vaborbactam, a beta-lactamase inhibitor, indicated for the treatment of patients 18 years and older with complicated urinary tract infections (cUTI) including pyelonephritis caused by designated susceptible bacteria.

Forms and strengths

1 g/2g / 1 g/2g

Injection (powder) for solution.

On the market

Earliest approval on file: August 29, 2017 Vabomere, Rempex; Drugs@FDA’s file, where older or withdrawn approvals can be missing
Generic approvals: No generic approved
Labelers listed (NDC): 1 of which 0 under generic applications, 1 under brand applications, repackagers included
Last listed patent: April 6, 2039 Vabomere injection; not a generic launch date

Supply and safety

Pharmacy cost (NADAC): Not in the survey
Shortage (FDA): No current entry
Recalls by its makers (FDA): No recall recorded
FAERS reports: 49 through July 30, 2026

What is meropenem and vaborbactam used for?

From the label: indications and usage
VABOMERE (meropenem and vaborbactam) is a combination of meropenem, a penem antibacterial, and vaborbactam, a beta-lactamase inhibitor, indicated for the treatment of patients 18 years and older with complicated urinary tract infections (cUTI) including pyelonephritis caused by designated susceptible bacteria. ( 1.1 ) To reduce the development of drug-resistant bacteria and maintain the effectiveness of VABOMERE and other antibacterial drugs, VABOMERE should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. ( 1.2 ) 1.1. […]

Conditions named in the indications of meropenem and vaborbactam's FDA labels, with every medicine labeled for each:

Urinary tract infections

From other meropenem and vaborbactam labels
Urinary tract infections: Complicated Urinary Tract Infections (cUTI), including Pyelonephritis VABOMERE ® is indicated for the treatment of patients 18 years of age and older with complicated urinary tract infections (cUTI) including pyelonephritis caused by the …

FDA pharmacologic class: Penem Antibacterial and beta Lactamase Inhibitor.

Source: FDA drug label (VABOMERE), NDA209776 (Rempex), as published by Melinta Therapeutics, LLC, effective February 27, 2026 (SPL set e237fd0f-3050-42a3-b43e-b6fb4824e93d), via openFDA; the full label on DailyMed

Is there a generic for meropenem and vaborbactam (Vabomere)?

No generic meropenem and vaborbactam is approved (Drugs@FDA, October 8, 2026).

The Orange Book lists 10 patents for Vabomere injection: the compound patent runs to August 29, 2031, and the last listed entry to April 6, 2039. A patent or exclusivity date is not the date a generic goes on sale: court cases and settlements move it either way.

2017 earliest approval on file
2039 last listed patent

Source: Drugs@FDA, FDA NDC Directory and the Orange Book (openFDA bulk files, October 8, 2026)

What does the meropenem and vaborbactam label say about other medicines?

The meropenem and vaborbactam label names 3 other medicines in its interaction, contraindication or warning sections. The sentences are the labels' own; a label lists what its studies and reports found, not every interaction.

Medicine named	Section	What the label says
Divalproex	drug interactions	Case reports in the literature have shown that co-administration of carbapenems, including meropenem, to patients receiving valproic acid or divalproex sodium results in a reduction in valproic acid concentrations.
Probenecid	drug interactions	Probenecid competes with meropenem for active tubular secretion, resulting in increased plasma concentrations of meropenem.
Valproic acid	drug interactions	Case reports in the literature have shown that co-administration of carbapenems, including meropenem, to patients receiving valproic acid or divalproex sodium results in a reduction in valproic acid concentrations.

Check meropenem and vaborbactam against other medicines

What do FAERS reports show for meropenem and vaborbactam?

The FDA Adverse Event Reporting System holds 49 reports that list meropenem and vaborbactam among the medicines taken, through July 30, 2026, each a report of something that happened, not proof the medicine caused it; 11 are coded as a death and 4 as a hospital stay. Counts follow how widely a medicine is used and watched, and they are not a measure of how risky it is.

The most reported reactions

Off Label Use (a use or a product term, not a reaction)19
Drug Ineffective For Unapproved Indication (a use or a product term, not a reaction)7
Death (an outcome recorded in the report)5
Erythema (named in the label)3
Hypersensitivity (named in the label)3
Rash (named in the label)3
Acute Kidney Injury2
Blood Culture Positive2

Source: FDA Adverse Event Reporting System (FAERS) via openFDA, reports through July 30, 2026

What else is labeled for the same conditions as meropenem and vaborbactam?

13 other medicines are given the same way (intravenous) and in the same FDA class as meropenem and vaborbactam or labeled mainly for the same use (urinary tract infections), the same class first. Urinary tract infections lists all 39 medicines labeled for it, by any route. The first 8 are below. They are listed as records, not as substitutes: whether one can replace another is a prescriber's decision.

Medicine	Shared indication	Generic labelers (intravenous)	Pharmacy cost	Shortage
Cilastatin and imipenem	Urinary tract infections	2 labelers	n/a	A presentation being discontinued
Avibactam and ceftazidime	Urinary tract infections	none listed	n/a	No current entry
Ceftolozane and tazobactam	Urinary tract infections	none listed	n/a	No current entry
Cilastatin and imipenem and relebactam	Urinary tract infections	none listed	n/a	A presentation being discontinued
Doxycycline	Urinary tract infections	20 labelers	n/a	A presentation being discontinued
Cefazolin	Urinary tract infections	7 labelers	$1.07 per vial 1 g vial	No current entry
Cefepime	Urinary tract infections	8 labelers	n/a	A presentation being discontinued
Ceftriaxone	Urinary tract infections	7 labelers	$1.44 per vial 1 g vial	No current entry

Every medicine labeled for the same conditions as meropenem and vaborbactam

Source: FDA drug labels (indications), NDC Directory, NADAC of October 7, 2026, FDA shortages (October 8, 2026)

What next?

Alternatives to meropenem and vaborbactam: 13 medicines for the same use
Other penem antibacterials: the pharmacologic class, with prices and generics
Meropenem and vaborbactam side effects: the label's list beside FAERS reports
Check an interaction: what two or more labels say about each other